SEC Form 4 · accession 0001638643-26-000026
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Patrick O'Day
Officer — Chairman & CEO · Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 4:14 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 1, 2026 | S | 11,900 | $126.0897 | D | 610,233 | D | |
| Common StockF3 | Jul 1, 2026 | S | 3,100 | $127.075 | D | 607,133 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
- F2Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F3Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.